2024
Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis
Karol A, Fujiwara Y, D'Ovidio T, Baldwin E, Joshi H, Doroshow D, Galsky M. Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis. Immunotherapy 2024, 16: 829-840. PMID: 39155854, PMCID: PMC11457654, DOI: 10.1080/1750743x.2024.2379230.Peer-Reviewed Original ResearchImmune checkpoint blockadeProgression-free survivalC-reactive proteinPeripheral blood cytokinesOverall survivalTumor-promoting inflammationCheckpoint blockadeInterleukin-6Interleukin-8Blood cytokinesOn-treatment declineIL-8 levelsTrial end pointsIL-6 levelsPharmacodynamic biomarkersInflammatory cytokinesEnd pointsResponse rateCytokinesMeta-analysisSystematic reviewBlockadeInflammationORRSurvivalC-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis
Fujiwara Y, Karol A, Joshi H, Reford E, Izadmehr S, Doroshow D, Galsky M. C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis. Critical Reviews In Oncology/Hematology 2024, 197: 104352. PMID: 38614269, PMCID: PMC11219184, DOI: 10.1016/j.critrevonc.2024.104352.Peer-Reviewed Original ResearchConceptsProgression-free survivalC-reactive proteinUrothelial carcinomaTumor-promoting inflammationOverall survivalCRP valuesHazard ratioPro-inflammatory tumor microenvironmentAssociated with shorter OSICB-treated patientsImmune checkpoint blockadeEvaluate survival outcomesRandom-effects model meta-analysesHigher CRP levelsSystematic reviewMeta-analysesLow CRP valuesCheckpoint blockadeShorter OSSurvival outcomesTumor microenvironmentCRP levelsPrognostic biomarkerCarcinomaPatients
2017
Trastuzumab emtansine: determining its role in management of HER2+ breast cancer
Doroshow DB, LoRusso PM. Trastuzumab emtansine: determining its role in management of HER2+ breast cancer. Future Oncology 2017, 14: 589-602. PMID: 29214842, DOI: 10.2217/fon-2017-0477.Peer-Reviewed Original ResearchConceptsBreast cancerAnti-HER2 monoclonal antibody trastuzumabManagement of HER2Single-agent trastuzumabTumor-directed cytotoxicityAcceptable toxicity profileFirst-line treatmentPhase III trialsMonoclonal antibody trastuzumabAdjuvant managementIII trialsOverall survivalAdvanced HER2Cardiac toxicityTrastuzumab emtansineAgent trastuzumabToxicity profileAntibody trastuzumabSystemic toxicityHER2CancerTrastuzumabStable linkerOngoing studiesToxicity